306 related articles for article (PubMed ID: 35674739)
21. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
22.
Kersting D; Sandach P; Sraieb M; Wiesweg M; Metzenmacher M; Darwiche K; Oezkan F; Bölükbas S; Stuschke M; Umutlu L; Nader M; Hamacher R; Fendler WP; Wienker J; Eberhardt WEE; Schuler M; Herrmann K; Hautzel H
J Nucl Med; 2023 Oct; 64(10):1540-1549. PubMed ID: 37474272
[TBL] [Abstract][Full Text] [Related]
23. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model.
Chereau E; Durand L; Frati A; Prignon A; Talbot JN; Rouzier R
Anticancer Res; 2013 Aug; 33(8):3015-9. PubMed ID: 23898054
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy.
Park H; Subramaniam RM
PET Clin; 2023 Apr; 18(2):223-231. PubMed ID: 36585338
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.
Kiesewetter B; Mazal P; Kretschmer-Chott E; Mayerhoefer ME; Raderer M
ESMO Open; 2022 Jun; 7(3):100478. PubMed ID: 35525183
[TBL] [Abstract][Full Text] [Related]
28. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
[TBL] [Abstract][Full Text] [Related]
29. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
30. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor-positive breast lesions on
Has Simsek D; Isik EG; Engin MN; Kuyumcu S; Mudun A; Sanli Y
Ann Nucl Med; 2021 Feb; 35(2):270-277. PubMed ID: 33400149
[TBL] [Abstract][Full Text] [Related]
32. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
Miederer M; Seidl S; Buck A; Scheidhauer K; Wester HJ; Schwaiger M; Perren A
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):48-52. PubMed ID: 18807033
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
35. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
36. Impact of FDG PET/CT Scan in Changing Management of Well-Differentiated Neuroendocrine Tumors With Ki67 Index Less Than or Equal to 5.
Choudhury S; Agrawal A; Rangarajan V; Puranik A; Bal M; Chaudhari V; Bhandare M; Purandare N; Shah S; Ramaswamy A; Ostwal V; Shrikhande SV
Clin Nucl Med; 2022 Nov; 47(11):e676-e681. PubMed ID: 36215398
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic analysis of [
Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
40. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]